Summary & Overview
CPT 52287: Cystoscopic Intradetrusor Neurolytic Injection for Overactive Bladder
CPT code 52287 represents a cystoscopic procedure that combines diagnostic bladder inspection with intradetrusor injection of a neurolytic agent to treat overactive bladder. This intervention is clinically important as it targets refractory detrusor overactivity when conservative measures have failed, and it has implications for specialty procedural billing, payer coverage policies, and site-of-service decision-making on a national scale.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for the procedure, how it is classified for billing purposes, and what to expect in terms of typical sites of service. The publication outlines common billing considerations and related procedural benchmarks where available. It also summarizes policy and payer coverage themes relevant to this class of cystoscopic therapeutic procedures.
The report is intended to inform clinicians, billing professionals, and policy analysts about the procedural definition and national relevance of CPT code 52287, the typical care settings where the procedure is delivered, and the types of payer policies that commonly affect authorization and reimbursement. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 52287 describes a cystoscopic procedure in which the clinician inspects the interior of the bladder, urethra, and ureteric openings using a cystoscope and then inserts a needle to inject a neurolytic agent into the bladder muscle to treat overactive bladder.
-
Service type: Cystoscopic intradetrusor neurolytic injection
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting; may also be performed in certain office-based procedure suites equipped for cystoscopy, depending on facility capabilities and patient needs.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old female with refractory overactive bladder (OAB) refractory to behavioral therapy and oral anticholinergic/beta-3 agonist medications presents for definitive therapy. The patient reports urinary urgency, frequency, and urge incontinence significantly impacting quality of life despite medication trials. After pre-procedure evaluation including history, focused pelvic/urinary exam, urinalysis to exclude infection, and counseling about risks/benefits, the urologist schedules an in-office or ambulatory surgical center procedure.
Under cystoscopic visualization, the provider performs a diagnostic cystoscopy to inspect the bladder mucosa, ureteric orifices, and urethra. Using the cystoscope, the provider inserts a fine needle transurethrally into the detrusor muscle and injects a neurolytic agent (commonly onabotulinumtoxinA) into multiple sites of the bladder wall to reduce detrusor overactivity. Post-procedure workflow includes monitoring for urinary retention, providing instructions for clean intermittent catheterization if retention occurs, arranging follow-up for symptom assessment and possible post-void residual measurement, and documenting informed consent and injection log (sites and units). Typical site of service is an outpatient procedure room, ambulatory surgical center (ASC), or hospital outpatient department (HOPD) depending on patient comorbidities and payer rules. Typical preauthorization, procedure note, and post-procedure documentation are part of the clinical workflow.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |